# A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07676006** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 36 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** GT737 Injection

## Key facts

- **NCT ID:** NCT07676006
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-05
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07676006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07676006, "A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07676006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*